ArticleCureus2025
Platelet and Red Cell Indices: A Potential Biomarker for Predicting Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic obstructive pulmonary disease (COPD) is a chronic progressive condition marked by inflammation and airflow limitation. Platelets and red blood cells play an important role in the pathogenesis of COPD and pulmonary hypertension (PH) by mediating thrombotic, inflammatory, and immune processes in the lungs. Blood indices, such as platelet-to-lymphocyte ratio (PLR), platelet distribution width (PDW), plateletcrit (PCT), red cell distribution width (RDW), mean platelet volume (MPV), and platelet count (PLT), have emerged as potential biomarkers for predicting the severity of PH. This study compares these indices and clinical profiles between COPD and non-COPD patients.
objectivesThis study aimed to compare the values of platelet indices and red cell indices between COPD and non-COPD patients and to investigate the predictive value of platelet indices and red cell indices for PH in COPD patients.
methodsThis cross-sectional study included 100 participants, categorized into two groups: COPD (n = 75) and non-COPD (n = 25). Laboratory parameters, including platelet and red cell indices, and pulmonary function parameters such as post-bronchodilator FEV1, forced vital capacity, and diffusion capacity of carbon monoxide (DLCO), were analyzed. PH severity (mild, moderate, and severe) was assessed by 2D-echo, and statistical significance was determined using t-tests, chi-square tests, and one-way analysis of variance.
resultsCOPD patients had lower lymphocyte counts (1,352.6 ± 483.9 vs. 2,253.4 ± 867.6; p < 0.001), higher PLR (253.8 ± 86.6 vs. 126.5 ± 79.4; p = 0.010), elevated RDW (15.4 ± 0.9 vs. 11.8 ± 1.4; p < 0.001), lower PDW (10.2 ± 1.6 vs. 11.2 ± 1.6), and higher PLT (318,720 ± 99,905.2 vs. 264,500 ± 11,2661.7) compared to non-COPD patients. PLR (p = 0.040), RDW (p <0.001), and DLCO (p = 0.025) predicted PH and increased with the severity of PH, while PDW, MPV, PCT, and PLT did not predict PH.
conclusionBlood markers, particularly RDW and PLR, are effective in predicting the severity of PH in COPD patients and can be used in early suspicion and diagnosis of PH in COPD patients, especially in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.